key: cord-0682820-2cg5zymu
authors: Pieri, Marina; Quaggiotti, Luisa; Fominskiy, Evgeny; Landoni, Giovanni; Calabrò, Maria Grazia; Ajello, Silvia; Bonizzoni, Matteo Aldo; Scandroglio, Anna Mara
title: Anticoagulation strategies in critically-ill SARS-CoV-2 patients: the role of direct thrombin inhibitors
date: 2022-03-08
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2022.03.004
sha: f218812c45ff3c28648daa00ffbb907424dda1db
doc_id: 682820
cord_uid: 2cg5zymu

Objectives To compare heparin-based anticoagulation and bivalirudin-based anticoagulation within the context of critically ill patients with SARS-CoV-2 infection. Design Observational study. Setting Intensive care unit of a University hospital. Participants and interventions Critically ill SARS-CoV-2 patients receiving full coagulation with heparin or bivalirudin. Measurements and main results Twenty-three patients received full anticoagulation with bivalirudin and 60 with heparin. Despite patients in the bivalirudin group had higher mortality risk scores (SAPS II was 60 ± 16 vs 39 ±7, p <0.001) and higher need of extracorporeal support compared to heparin group, hospital mortality was comparable (57% vs 45, p=0.3). No difference in thromboembolic complications was observed, and bleeding events were more frequent in patients treated with bivalirudin (65% vs 40%,p=0.01). Similar results were confirmed in the subgroup analysis of patients undergoing intravenous anticoagulation: in addiction to comparable thrombotic complications occurrence and thrombocytopenia rate, however, no difference in bleeding rate was observed (65% vs 35%, p=0.08). Conclusions Although heparin is the most used anticoagulant in the intensive care setting, a bivalirudin-based anticoagulation was safe and effective in a cohort of SARS-CoV-2 critically ill patients. Bivalirudin may be given full consideration as anticoagulation strategy for SARS-CoV-2 critically ill patients, especially in those with thrombocytopenia and on extracorporeal support.

SARS-CoV-2 infection is responsible for a variable spectrum of clinical manifestations, up to severe respiratory and cardiac injury requiring intensive care unit (ICU) treatment [1] [2] . SARS-CoV-2 induced proinflammatory state and its associated endothelial lung injury have been found to be responsible for a prothrombotic state, involving both large vessels and microcirculation [3] [4] [5] . In critically ill SARS-CoV-2 patients, clinical deterioration toward multi-organ failure (MOF) appears to be mediated both by respiratory failure and microvascular systemic involvement [6] : an inherent hypercoagulable state with derangements in laboratory parameters (elevations of D-dimer, fibrin degradation products, prothrombin time, and aPTT), and both venous and arterial thromboembolic disease are common findings in these patients [7] [8] . For this reason, great attention has been focused on anticoagulation as a prophylactic and therapeutic strategy within the management of SARS-CoV-2 infection and its associated complications [9] [10] . Heparin, 4 traditionally used as first-line anticoagulation strategy in critically ill patients, presents limitations, including some variability in the anticoagulant effect including bleeding risk, complex titration based on activated partial thromboplastin time (aPTT) in the critically ill, and the risk of heparin-induced thrombocytopenia (HIT) [11] . On the contrary, the use of direct thrombin inhibitors, such as bivalirudin, may represent a valid anticoagulation strategy in critically ill patients, due to anticoagulation effect stability even at low drug dose, possibly lower bleeding risk and reduced blood cell activation against platelets, thus avoiding the risk of HIT [12] [13] . Bivalirudin has the ability to bind both the circulating and the clot-bind fibrin, and has been shown to reduce the risk of bleeding in critically ill patients on venovenous extracorporeal membrane oxygenation (VV ECMO) compared to heparin [14] [15] . However, reports on the use of bivalirudin in critically ill SARS-CoV-2 infection, beyond extracorporeal support itself, are lacking. The aim of the present observational study was to compare anticoagulation strategies, bivalirudin versus heparin, in critically-ill patients admitted to intensive care unit (ICU) with respiratory failure due SARS-CoV-2 infection.

We performed an observational analytical study involving critically-ill SARS-CoV-2 patients admitted to

Intensive Care Unit at our Institute from February 2020 to May 2020 and who were administered anticoagulation in a therapeutic range. The study is in compliance with the Declaration of Helsinki. Data collection was performed in consensus with ethical norms and with the local ethical committee approval.

Demographic, clinical parameters, vital signs and outcome data were registered for all patients. Patients' data were electronically stored: all data were anonymized prior to insertion into the database. Primary endpoints of the study were to assess the safety and efficacy of bivalirudin therapy in terms of drug related adverse event and efficacy in the prevention of thrombotic event compared to heparin. Secondary endpoints were comparison of bleeding complications rate and hospital survival.

According to our institutional protocol, patients received heparin as routine anticoagulation, while they were administered bivalirudin in the presence of extracorporeal devices (venovenous extracorporeal membrane oxygenation (V-V ECMO); mechanical circulatory support, etc...) or thrombocytopenia with suspect of HIT. Intravenous anticoagulation was performed in unstable patients and in patients with extracorporeal devices or organ failure needing close drug titration. Patients treated with bivalirudin received a starting intravenous continuous infusion of 0.025 mg/kg/h without any bolus, while patients administered intravenous heparin had a starting dose of 400 U/h. Low starting dosages were administered as routine practice in critically ill patients at our institution, and in the absence of complications, they were rapidly increased after few hours according to a minimum 3 times a day monitoring of aPTT with the target of 60 seconds in patients undergoing full anticoagulation.

Bleeding episodes were recorded according to GUSTO bleeding criteria [16] . Thrombotic episodes were assessed by collecting data concerning ischemic stroke, ischemic peripheral ischemia, pulmonary embolism and any other type of thrombotic event; the parameter "other thrombotic complications" included thrombotic events that were not included in aforementioned cases (such as acute coronary syndrome and venous thrombosis). Thrombocytopenia was defined mild, moderate or severe according to platelet count (<100,000/microL, <50,000/microL, <10,000 microL, respectively). Vasoactive agents' and inotropes' dose was standardized with Vasoactive Inotropic Score (VIS) calculation [17] . HIT was presumed if the platelet count was less than 100 10 9 /L or decreased more than 50% from the baseline in a patient treated with heparin, thus triggering the performance of an immunologic test (ELISA). If the results were questionable, a heparin-induced platelet aggregation assay also was performed. When HIT was presumed, all sources of heparin were removed.

Data regarding continuous variables with a bell-shaped distribution were presented with mean ± standard deviation. Median and interquartile ranges were reported for not-normally distributed variables. Number and prevalence proportion were recorded for dichotomous variables. T-test and Mann-Whitney U test [18] 6 were used to compare variables with normal or not-normal distribution between groups. Dichotomous variables were further analyzed according to Pearson chi-square calculation to assess statistical significance. A p-value < 0.05 was considered statistically significant. We performed a comparison between patients receiving full dose anticoagulation with bivalirudin and heparin. Furthermore, further analysis was performed to compare subgroups of patients undergoing intravenous anticoagulation (either bivalirudin or heparin) to assess data in a more homogenous population. Another comparison between bivalirudin dose in SARS-CoV-2 versus non-SARS-CoV-2 critically ill patients was performed with data from a population of 89 non SARS-CoV-2 critically ill patients admitted at our institute who were treated with bivalirudin by the same team [19] .

Overall, 129 ICU Sars-CoV-2 patients (110 males -85%-and 19 females -15%-) received anticoagulation in the study period: 23 (17%) received bivalirudin and 106 patients (82%) were administered heparin , as 

Data regarding baseline characteristics and anamnestic data of the 60 patients treated with heparin and 23 patients administered bivalirudin with full anticoagulation target are reported in Table 1 , while clinical data of patients receiving therapeutic anticoagulation strategy are presented in Table 2 . Higher shock degree and illness severity of the bivalirudin group compared to the heparin counterpart was demonstrated by higher SAPS II score (60 ± 16 vs 39 ±7, p <0.001) and need of extracorporeal support and devices (Table 2) .

Despite this difference, the need to temporary discontinuation of anticoagulation due to bleeding was not increased (27% in bivalirudin group, 37% in heparin group; p = 0.4). In Table 3 , data concerning outcomes and complications of patients receiving full-dose anticoagulation strategy are shown. Efficacy of the two anticoagulation strategies in preventing thromboembolic events was comparable. In particular, reported thromboembolic events were ischemic stroke (4% bivalirudin group; 8.3% heparin group; p=0.5), ischemic peripheral complications (18% bivalirudin group; 10% heparin group; p=0.3), pulmonary embolism (27% bivalirudin group; 20% heparin group; p = 0.4), and other thrombotic complications (32% bivalirudin group; 35% heparin group; p = 0.8). The overall bleeding rate was higher among bivalirudin group (65%) compared to heparin group (40%) (p = 0.01), in line with the higher bleeding risk associated to extracorporeal support devices. In particular, major bleeding episodes were higher in bivalirudin group compared to heparin group (26% among bivalirudin group and 7% among heparin group, p = 0.01). This finding was associated with a higher need for red blood cells and fresh frozen plasma transfusions in the bivalirudin group (17(7.5-27)) red blood cells units among bivalirudin group versus 1 (0-3) in the heparin group, p = 0.2; 0 (0-8) fresh frozen plasma transfusions in the bivalirudin group and 0 (0-0) in the heparin group, (p=0-0003) (table 3) .

All the 6 patients in the bivalirudin group who experienced major bleeding were on VV ECMO due to refractory ARDS, and 4 had platelet count <50,000 microL: 4 patients had intrathoracic bleeding (after a mean of 19 days of support), 1 gastrointestinal bleeding (after 26 days of support) and the last patient intracranial bleeding (after 11 days of support). However, no difference in the rate of surgical procedures due to bleeding events was recorded (9% among bivalirudin group and 10% among heparin group; p = 0.9).

Moderate and severe thrombocytopenic episodes were higher among the bivalirudin group (p = 0.02).

8 ECMO duration was notably high: 25 (10-46) days, with 50% of patients having ECMO run longer than one month (maximum length 56 days). No case of heparin induced thrombocytopenia was recorded.

ICU stay was shorter among heparin group compared to bivalirudin patients (14 (11-25) days versus 33 (20- 48.5) days, p < 0.0001). Notably, no statistical significant difference in ICU mortality and hospital mortality was observed: ICU mortality was 57% in the bivalirudin group and 40% in the heparin group, p = 0.2; hospital mortality was 57% in the bivalirudin group and 45% in the heparin group, p = 0.3.

Demographic characteristics, clinical management and outcomes of all patients treated with intravenous heparin compared to bivalirudin are reported in Supplementary tables 1,2 and 3 of supplementary material. Patients in the bivalirudin group had higher SAPS II score (with consequent high predicted mortality risk) compared to heparin (60 ±16 vs 44 ± 7, p=0.01), and higher need for extracorporeal devices (supplementary table 2) , thus confirming what observed in the overall population. Again, thrombotic complication rate (ischemic stroke, pulmonary embolism, peripheral ischemia and any other type of thrombotic event) was low and similar between groups, as shown in supplementary table 3). D-dimers peak value was 5 (3-13) microgr/ml in the bivalirudin group and 14 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) microgr/ml in the heparin group. In contrast to what observed in the general population, no statistical significant difference neither in the overall bleeding rate was observed (65% in the bivalirudin group vs 36% in the heparin group, p=0.08), nor with reference to major, moderate or minor bleeding rate specifically (p=0.2, p=0.1, p=0.3, respectively) (supplementary table 3) . Similarly, no difference in thrombocytopenia rate was documented between bivalirudin and heparin group in this subgroup analysis. Overall hospital mortality was comparable between the 2 groups (57% in the bivalirudin group, 57% in heparin group (p = 0.9)).

Bivalirudin dosage administered to bivalirudin group was further compared to bivalirudin dosage administered to a control group of 89 critically ill patients negative for SARS-CoV-2 infection. In Supplementary table 4 (Supplementary material), daily dose of bivalirudin of the first 6 days of ICU admission was reported. Median bivalirudin dose administered to SARS-CoV-2 patients was within a range from 0.04 ml/kg/h to 0.108 mg/kg/h, higher than the dose administered in the control group (range of 0.014 mg/kg/h to 0.044 mg/kg/h) (p < 0.05).

We reported data and results of different anticoagulation strategies in a large population of critically ill patients due to SARS-CoV-2 infection. Our study demonstrated that intravenous anticoagulation with the direct thrombin inhibitor bivalirudin was a safe and an effective strategy even in the most extremely ill patients. Indeed, although being reserved to highly compromised patients in our practice (i.e. patients requiring extracorporeal support, patients with severe thrombocytopenia), anticoagulation with bivalirudin allowed adequate antithrombotic effect compared to heparin, even at low starting dose.

Despite patients treated with bivalirudin were more compromised than the heparin counterpart, as shown by higher mortality risk score and need for extracorporeal support and invasiveness of care, the use of bivalirudin was proved to be associated with an equal overall survival compared to heparin (overall mortality 57% in bivalirudin group; 42% in heparin group; p = 0.2). This was further confirmed in the intravenous anticoagulation subgroup (mortality 57% in both groups, p=0.9).

Patients in the bivalirudin group had higher incidence of thrombocytopenia: however, this did not translate into large amount of platelet transfusions. Risk factors for thrombocytopenia were several in this population (shock, Sars-CoV-2 infection, therapies, mechanical circulatory support) and above all exposure to heparin: they might also act concomitantly. On the contrary, severe bleeding and need for red blood cells and fresh frozen plasma transfusions were higher in bivalirudin group compared to heparin patients (table 3) . The higher rate of bleeding and transfusions need is in our opinion to be linked to the extreme sickness of the patients in the bivalirudin group. Furthermore, in the subgroup analysis on patients treated with intravenous anticoagulant, which represent the subgroup of most unstable patients, no significant difference in the bleeding rate, thrombocytopenia incidence and fresh frozen plasma transfusions incidence was observed (supplementary table 1-3).

A growing body of literature has been supported the use of bivalirudin in critically ill patients, especially in case of extracorporeal support, since these patients present multiple events of coagulation activation and precarious balance between bleeding and thrombosis [13, [20] [21] . A reduction in the bleeding rate of VV ECMO patients treated with bivalirudin compared to heparin has also been specifically documented in a homogenous population treated with either one or the other anticoagulant [14] . In addition, preliminary evidence exists also on the use of bivalirudin to mitigate the thrombotic risk determined by the peculiar setting of SARS-CoV-2 infection [15, 22] . Our data are in line with existing literature, and the fact that we observed comparable survival between patients treated with bivalirudin and heparin further supports the efficacy and safety of the use of direct thrombin inhibitors in such a complex clinical context. Furthermore, in the setting of SARS-CoV-2 infection, interestingly, a higher risk for anti PF4 antibodies development has been claimed, although not univocally documented [23] [24] [25] : this may represent another element to be taken into consideration in the choice of the anticoagulation strategy. At the moment, large prospective randomized trials on the use of bivalirudin in patients with SARS-CoV-2 infection are on the way and results will be provided in the next future [26] .

Our data also pointed out that bivalirudin dose administered to SARS-CoV-2 affected patients was higher compared to bivalirudin drug administered to a control group of critically-ill patients negative to SARS-CoV-11 2 infection. This finding is in line with very recent literature [27] and supports the clinical perception that the hypercoagulability status induced by SARS-CoV-2 infection has relevant clinical impact. Indeed, recommendations supporting higher anticoagulation targets when dealing with ECMO and SARS-CoV-2 infection have also been developed [28] . We argue that reaching the appropriate anticoagulation target with higher doses of bivalirudin that what generally requested played a key role in downregulating thrombotic patterns activation: namely we observed a low thrombotic complication rate, and this was confirmed also in ECMO patients. At the same time, a word of caution is mandatory in the interpretation of coagulation tests, such as aPTT, since they are influenced by the levels of coagulation factors. Namely, levels of factor VIII have been shown to be increased in patients with Sars-CoV-2 infection [29] , and this might results in assay artifacts, such as shorter aPTT. In the light of this, we might have administered excessively high bivalirudin dosages to our patients, but this did not translated into an increased bleeding risk in the subgroup analysis of patients undergoing intravenous anticoagulation with aPTT monitoring.

Finally, anticoagulation with bivalirudin proved to be safe and effective at least as heparin in our experience: although no specific antidote exists, it has a half-life of 25 min [30] . Since it is 20% cleared by kidneys, dose adjustments were needed in case of renal failure and dose increase may be needed in case of renal replacement therapy [31, 32] : these may be safely performed following aPTT in our experience [19] .

The study also has some limitations: first the retrospective study design. Moreover, the most compromised patients pertained to the bivalirudin group, since the control arm, represented by heparin group, were not comparable in terms of critical conditions and organ failure. Another confounding factor was that patients in the heparin group were administered different types of drugs (unfractionated heparin vs low molecular weight heparin) through different administration routes. However, we also performed a subgroup analysis of the most critically ill patients treated with intravenous drugs. Although we might argue that bivalirudin might be a valid alternative to heparin in this clinical context based on our data, we are fully aware that the present study is underpowered to assess the impact of anticoagulation regimen on survival and therefore no conclusion is to be drawn on this topic. Furthermore, this retrospective study was conducted on patients hospitalized from February 2020 to May 2020, when guidelines regarding SARS-CoV-2 infection management were lacking and recommendations were poorly evidenced based. Very recent meta-analysis and multicentric studies are providing new perspectives regarding anticoagulation strategies for critically-ill SARS-CoV-2 patients [33] [34] . As a matter of fact, anticoagulant drugs other than heparin represent a new powerful therapeutic tool that may allow to overcome heparin adverse reactions [35] . Moreover, direct thrombin inhibitors are now taken into consideration as anticoagulation strategy to face vaccine-induced immune thrombotic thrombocytopenia (VITT), a new pro-thrombotic condition that cannot be coped with heparin [36] . Finally, we provided data on bivalirudin dose needed in a contemporary non-Sars-CoV-2 critically ill patient population to be compared with Sars-CoV-2 patients, but a similar analysis could not be performed also in the heparin group.

While heparin is the most extensively used anticoagulant drug, bivalirudin has a valuable good safety and efficacy profile in the most critically ill patients, even in those on extracorporeal support. In addition to anticoagulant effect, by reducing the thrombin-mediated activation of platelets, bivalirudin also shows antiplatelet effects [37] . Furthermore, through the tight cross-talk between coagulation and inflammation, it might also affect inflammatory patterns [38] Its pleiotropic clinical effects should be further investigated also in the perspective of inflammatory downregulation. Prospective trials are needed to assess possible survival implications.

The study was supported by departmental funds.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

The authors declare that they have no competing interests. 

MD: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing -original draft

Writing -review & editing

MD: Conceptualization; Data curation; Formal analysis; Investigation; Methodology

Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing -original draft

MD: Conceptualization; Data curation; Formal analysis; Investigation; Methodology

Project administration; Resources

PhD: Funding acquisition; Project administration; Validation; Visualization; Writingreview & editing; Supervision

MD: Conceptualization; Data curation; Supervision; Validation; Visualization

Roles/Writing -original draft;Writing -review & editing

MD: Conceptualization; Data curation; Supervision; Validation; Visualization; Roles/Writingoriginal draft

MD: Resources; Supervision; Writing -review & editing

MD: Data ccuration; Visualization

Roles/Writing -original draft; Writing -review & editing

MD: Funding acquisition

Extracorporeal Life Support Organization registry

Critically-ill COVID-19 patient

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

COVID-19 coagulopathy: is it disseminated intravascular coagulation?

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

MicroCLOTS pathophysiology in COVID 19

Epub ahead of print

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Heparin-induced thrombocytopenia

The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results

Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction

Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis

On a test of whether one of two random variables is stochastically larger than the other

Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients

Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a casecontrol study

Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices

Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2-Associated Acute Respiratory Failure

COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies

Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy

Heparin-Induced Thrombocytopenia in COVID

Anticoagulation in critically ill patients on mechanical ventilation suffering from

The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support

Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers

19 coagulopathy: An in-depth analysis of the coagulation system

Modification strategies to improve the membrane hemocompatibility in extracorporeal membrane oxygenator (ECMO) Adv

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With

Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Autoimmune heparin-induced thrombocytopenia

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Direct thrombin inhibitors

Cross Talk Pathways Between Coagulation and Inflammation